Nika Pharmaceuticals Financials

No, Nika Pharmaceuticals (NIKA) reported a net income of -$76K in fiscal year 2025.

Nika Pharmaceuticals (NIKA) reported diluted earnings per share of $0.00 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Nika Pharmaceuticals (NIKA) generated -$80K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

Nika Pharmaceuticals (NIKA) had $21K in total assets as of fiscal year 2025, including both current and long-term assets.

Nika Pharmaceuticals (NIKA) had 1.05B shares outstanding as of fiscal year 2025.

Nika Pharmaceuticals (NIKA) had a current ratio of 0.07 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

Nika Pharmaceuticals (NIKA) had a debt-to-equity ratio of -1.07 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

Nika Pharmaceuticals (NIKA) had a return on assets of -363.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Based on fiscal year 2025 data, Nika Pharmaceuticals (NIKA) had $2K in cash against an annual operating cash burn of $80K. This gives an estimated cash runway of approximately 0 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Nika Pharmaceuticals (NIKA) has negative shareholder equity of -$298K as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

Nika Pharmaceuticals (NIKA) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Nika Pharmaceuticals (NIKA) has an earnings quality ratio of 1.04x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.